Business Insider

Incyte’s CDK2 Inhibitor Shows Promise but Warrants Hold Rating Amid Uncertainty

Jessica Fye, an analyst from J.P. Morgan, has initiated a new Hold rating on Incyte (INCY). Jessica Fye has given her Hold rating due to a combination of factors regarding Incyte’s stock. Firstly, the ...
Business Wire

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...
Hosted on MSN

Incyte's SWOT analysis: strong pipeline faces patent cliff challenges

Incyte (NASDAQ:INCY) Corporation, a biopharmaceutical company specializing in proprietary therapeutics with a market capitalization of $14 billion, finds itself at a critical juncture as it navigates ...
Business Insider

Incyte’s Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics

JMP Securities analyst Reni Benjamin has maintained their neutral stance on INCY stock, giving a Hold rating yesterday. Reni Benjamin has given his Hold rating due to a combination of factors ...
Nasdaq

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology ...

- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz®) results in squamous cell anal carcinoma (SCAC); filing of supplemental Biologics License Application (sBLA) in SCAC planned by year ...